Memory Deficit Clinical Trial
Official title:
Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.
The purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function. This is a parallel distribution: a group of patients will be treated with a combination Panax Ginseng + Ginkgo Biloba + multivitamin + Polyminerals (EMS), and another group with Ginkgo Biloba (Tebonin ®).
STUDY DESIGN: - multicenter, phase III, double-blind, randomized entry of patients, prospective and comparative - The duration of the study: 60 days - 3 visits (days 1, 30 and 60) - Evaluate the effectiveness of the association - Evaluate the safety of the combination - Adverse events evaluation ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00283309 -
Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
|
Phase 4 | |
| Completed |
NCT05462977 -
Rhythmically Entrained Exercise in Community-Dwelling Older Adults
|
N/A | |
| Completed |
NCT00464659 -
Protocol Memory Deficit in Patients With Obstructive Sleep Apnea Syndrome
|
N/A |